This is a phase 1, placebo-controlled, blinded, randomized, dose escalation study of PBI-0451
in healthy subjects. PBI-0451 is a new chemical entity and inhibitor of the main protease of
coronaviruses, including the SARS-CoV-2 that causes COVID-19 disease. The study is designed
to evaluate the safety, tolerability and pharmacokinetics of PBI-0451 after single and
multiple ascending doses and also to explore drug-drug interaction potential of PBI-0451.